367 related articles for article (PubMed ID: 11577797)
1. Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus.
McKeage K; Goa KL
Drugs; 2001; 61(11):1599-624. PubMed ID: 11577797
[TBL] [Abstract][Full Text] [Related]
2. Spotlight on insulin glargine in type 1 and 2 diabetes mellitus.
McKeage K; Goa KL
Treat Endocrinol; 2002; 1(1):55-8. PubMed ID: 15765621
[TBL] [Abstract][Full Text] [Related]
3. Insulin glargine: an updated review of its use in the management of diabetes mellitus.
Dunn CJ; Plosker GL; Keating GM; McKeage K; Scott LJ
Drugs; 2003; 63(16):1743-78. PubMed ID: 12904090
[TBL] [Abstract][Full Text] [Related]
4. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
5. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine.
Warren E; Weatherley-Jones E; Chilcott J; Beverley C
Health Technol Assess; 2004 Nov; 8(45):iii, 1-57. PubMed ID: 15525480
[TBL] [Abstract][Full Text] [Related]
6. Insulin glargine: a systematic review of a long-acting insulin analogue.
Wang F; Carabino JM; Vergara CM
Clin Ther; 2003 Jun; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485
[TBL] [Abstract][Full Text] [Related]
7. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
[TBL] [Abstract][Full Text] [Related]
8. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
Hemmingsen B; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
[TBL] [Abstract][Full Text] [Related]
9. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus.
Mullins P; Sharplin P; Yki-Jarvinen H; Riddle MC; Haring HU
Clin Ther; 2007 Aug; 29(8):1607-19. PubMed ID: 17919543
[TBL] [Abstract][Full Text] [Related]
10. Insulin detemir: a review of its use in the management of diabetes mellitus.
Keating GM
Drugs; 2012 Dec; 72(17):2255-87. PubMed ID: 23110609
[TBL] [Abstract][Full Text] [Related]
11. Insulin glargine.
Gillies PS; Figgitt DP; Lamb HM
Drugs; 2000 Feb; 59(2):253-60; discussion 261-2. PubMed ID: 10730548
[TBL] [Abstract][Full Text] [Related]
12. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin.
Porcellati F; Rossetti P; Pampanelli S; Fanelli CG; Torlone E; Scionti L; Perriello G; Bolli GB
Diabet Med; 2004 Nov; 21(11):1213-20. PubMed ID: 15498088
[TBL] [Abstract][Full Text] [Related]
13. Insulin glargine: a new long-acting insulin product.
Reinhart L; Panning CA
Am J Health Syst Pharm; 2002 Apr; 59(7):643-9. PubMed ID: 11944604
[TBL] [Abstract][Full Text] [Related]
14. Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy.
Owens DR; Traylor L; Mullins P; Landgraf W
Diabetes Res Clin Pract; 2017 Feb; 124():57-65. PubMed ID: 28092788
[TBL] [Abstract][Full Text] [Related]
15. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
Fulcher GR; Gilbert RE; Yue DK
Intern Med J; 2005 Sep; 35(9):536-42. PubMed ID: 16105155
[TBL] [Abstract][Full Text] [Related]
16. Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes.
Bolli GB; Songini M; Trovati M; Del Prato S; Ghirlanda G; Cordera R; Trevisan R; Riccardi G; Noacco C
Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):571-9. PubMed ID: 18676131
[TBL] [Abstract][Full Text] [Related]
17. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study.
Rosenstock J; Fonseca V; McGill JB; Riddle M; Hallé JP; Hramiak I; Johnston P; Davis M
Diabetologia; 2009 Sep; 52(9):1778-88. PubMed ID: 19526210
[TBL] [Abstract][Full Text] [Related]
18. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.
Home PD; Bolli GB; Mathieu C; Deerochanawong C; Landgraf W; Candelas C; Pilorget V; Dain MP; Riddle MC
Diabetes Obes Metab; 2015 Jan; 17(1):15-22. PubMed ID: 24957785
[TBL] [Abstract][Full Text] [Related]
19. Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE.
Dornhorst A; Lüddeke HJ; Koenen C; Meriläinen M; King A; Robinson A; Sreenan S;
Diabetes Obes Metab; 2008 Jan; 10(1):75-81. PubMed ID: 18034846
[TBL] [Abstract][Full Text] [Related]
20. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes.
Home PD; Rosskamp R; Forjanic-Klapproth J; Dressler A;
Diabetes Metab Res Rev; 2005; 21(6):545-53. PubMed ID: 16021649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
